March 6, 2019 / 1:09 PM / 18 days ago

Vertex's cystic fibrosis therapy meets goal of late-stage studies

March 6 (Reuters) - Vertex Pharmaceuticals Inc said on Wednesday its triple-combination therapy showed improvement in lung function for people with cystic fibrosis (CF).

The combination therapy - consisting its experimental agent VX-445 and its other CF drugs Kalydeco and tezacaftor - met the main goal of two late-stage studies, showing improvement in lung function.

Reporting by Saumya Sibi Joseph and Manas Mishra in Bengaluru; Editing by Shinjini Ganguli

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below